PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...
Palisade Bio, Inc. (NASDAQ: PALI) shares barely cleared breakeven Wednesday. The company, a clinical-stage biopharmaceutical concern developing next-generation, once-daily, oral PDE4 inhibitor ...
Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing ...
Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...
We reviewed all colonoscopic procedures performed in the endoscopy center of Ajou University Hospital, which is a 1000-bed teaching hospital, between 1 January 2005 and 31 December 2005. Six ...
A woman, aged 61, had a colonoscopy because of a positive result from a fecal occult blood test. No abnormalities were detected in the colon but endoscopic examination of the terminal ileum showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback